Show simple item record

In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.

dc.contributor.authorMalay, Sheila
dc.contributor.authorRoblin, Patricia M
dc.contributor.authorReznik, Tamara
dc.contributor.authorKutlin, Andrei
dc.contributor.authorHammerschlag, Margaret R
dc.date.accessioned2023-07-05T15:53:08Z
dc.date.available2023-07-05T15:53:08Z
dc.date.issued2002-02
dc.identifier.citationMalay S, Roblin PM, Reznik T, Kutlin A, Hammerschlag MR. In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother. 2002 Feb;46(2):517-8. doi: 10.1128/AAC.46.2.517-518.2002. PMID: 11796366; PMCID: PMC127069.en_US
dc.identifier.issn0066-4804
dc.identifier.pmid11796366
dc.identifier.urihttp://hdl.handle.net/20.500.12648/10363
dc.description.abstractThe in vitro activities of BMS-284756 (a novel des-fluoroquinolone), levofloxacin, moxifloxacin, and clarithromycin were tested against 5 strains of Chlamydia trachomatis and 20 isolates of Chlamydia pneumoniae. The MIC at which 90% of the isolates were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed by BMS-284756 for all isolates of C. pneumoniae and C. trachomatis was 0.015 microg/ml (range, 0.015 to 0.03 microg/ml). BMS-284756 was the most active quinolone tested.
dc.language.isoenen_US
dc.relation.urlhttps://journals.asm.org/doi/epub/10.1128/aac.46.2.517-518.2002en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleIn vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleAntimicrobial agents and chemotherapyen_US
dc.source.volume46
dc.source.issue2
dc.source.beginpage517
dc.source.endpage8
dc.source.countryUnited States
dc.description.versionVoRen_US
refterms.dateFOA2023-07-05T15:53:09Z
html.description.abstractThe in vitro activities of BMS-284756 (a novel des-fluoroquinolone), levofloxacin, moxifloxacin, and clarithromycin were tested against 5 strains of Chlamydia trachomatis and 20 isolates of Chlamydia pneumoniae. The MIC at which 90% of the isolates were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed by BMS-284756 for all isolates of C. pneumoniae and C. trachomatis was 0.015 microg/ml (range, 0.015 to 0.03 microg/ml). BMS-284756 was the most active quinolone tested.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentPediatricsen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalAntimicrobial agents and chemotherapy
dc.identifier.issue2en_US


Files in this item

Thumbnail
Name:
aac.46.2.517-518.2002.pdf
Size:
39.10Kb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International